The planned upgrades include the introduction of single-use technology for flexible ADC manufacturing, along with a recently optimised plant layout and revamping of the heating, ventilation, air conditioning systems, which has resulted in a larger ADC production area.
The addition of single-use manufacturing systems will reduce potential product contamination risks and allow for increased manufacturing capacity of existing and novel ADC platforms.
Lonza’s clinical ADC plant in Visp produces toxicology lots, early-phase GMP lots and GMP re-supply lots to support ongoing clinical trials for several different product candidates.
“We have witnessed significant growth in the early-phase ADC market in the last two years,” said Stefan Stoffel, senior vice president of operations for Lonza’s Pharma&Biotech segment. “This new investment is necessary to continue to support the growing pipeline of novel ADC platforms from our customers by offering them new manufacturing technology with increased throughput.”
© FoodBev Media Ltd 2024